This baseline inflammatory signature disappears after infusion of nivolumab, and the clinical responses are characterized by the temporary expansion of polyclonal CD4+ T-cell populations, the contraction of AML subsets exhibiting megakaryocytic characteristics, and elevated PD-L1 expression (111). This evidence concerns the gene CD274 and acute myeloid leukemia.